2022 Speakers

Speakers

Expand/Collapse

Adi Mor
Chief Scientific Officer
Chemomab

Day 1 - Stream B - Morning

11:00 am | Crossing the divide: Leveraging Fibrosis- Inflammatory Biomarkers to Inform Clinical Trial Design

Akshay Krishnamurty
Senior Scientist, Cancer Immunology
Genentech

Andrew Leask
Professor
University of Saskatchewan

Andrzej Krolewski
Senior Investigator
Joslin Diabetes Centre

Day 1 - Stream B - Afternoon

2:30 pm | Discussing Biomarkers of Progressive Kidney Function Decline as Biomarkers of Kidney Fibrosis

Anissa Kalinowski
Chief Executive Officer
Halo Biosciences

Day Two

Friday, November 11, 2022

9:20 am | Pipeline Peak 3: Clinical Validation of a New Therapeutic Target: Inhibiting Hyaluronan to Treat Lung Fibrosis & Pulmonary Hypertension

Anjali Pandey
Senior Vice President Nonclinical R&D & Chemistry
ARIA Pharmaceuticals

Day Two

Friday, November 11, 2022

9:00 am | Pipeline Peak 2: Leveraging AI From Human Derived Data to Identify Drug Leads & Establish Efficacy for IPF & NASH

Anna Zargoska
Senior Research Scientist II
Gilead

Day Two

Friday, November 11, 2022

11:30 am | Looking Beyond IPF & NASH: What Can We Learn About Fibrosis From Chronic Autoimmune Diseases?

Cheryl Nickerson-Nutter
Vice President– Research & Development
Three Lakes Partners

Day Two

Friday, November 11, 2022

8:00 am | Discussion Panel: How to Play With the FDA? Engaging & Creating A Dialogue With Regulatory Bodies to Design Trials Effectively

Christian Hesslinger
Senior Expert- Translational Medicine & Biomarker
Boehringer Ingelheim

Day One

Thursday, November 10, 2022

8:00 am | Discussion Panel: Debating the Commonalities & Disparities Between the Different Fibrotic Disease Indications & Organ Specific Fibroses

Christina Wenglen
Head of Research
Anamar

Day One

Thursday, November 10, 2022

5:00 pm | Understanding the Role of the 5-HT2B Receptor in Fibrosis with Special Focus on Systemic Sclerosis-ILD

Day Two

Friday, November 11, 2022

2:30 pm | Panel Discussion: What’s Missing? Uncovering the Questions that Need to Be Answered in the Next 12 Months of Research & Drug Development

David Lagares
Director & Head of Matrix & Mechanobiology Program
Massachusetts General Hospital

Day Two

Friday, November 11, 2022

1:00 pm | Targeting DuroTaxis in Organ Fibrosis & Cancer

Elizabeth Redente
Associate Professor
National Jewish Health

Eric White
Senior Clinical Program Lead
Boehringer Ingelheim

Day 1 - Stream B - Afternoon

1:45 pm |
Panel Discussion:
Validating Biomarkers Across Trials & Diseases: Illuminating Learnings from the Lung, Kidney & Liver

Day Two

Friday, November 11, 2022

8:00 am | Discussion Panel: How to Play With the FDA? Engaging & Creating A Dialogue With Regulatory Bodies to Design Trials Effectively

Geoffrey Teixeira
Head of Fibrosis
Alentis Therapeutics

Day One

Thursday, November 10, 2022

9:30 am | Integrating Multi-Omics Approaches to Identify Relevant Biomarkers for Fibrosis Clinical Trials

Haig Aghajanian
Co-Founder & Vice President – Research
Capstan Therapeutics

Harry Karmouty-Quintana
Associate Professor
The University of Texas Health Science Center at Houston

Day One

Thursday, November 10, 2022

4:00 pm | Discussing SIX1 Driven Mechanisms in Lung & Skin Fibrosis: A Potential for Gene Therapy?

Herman Steen
Co-Founder & Chief Executive Officer
BiOrion Technologies

Day One

Thursday, November 10, 2022

8:30 am | Discussing Myofibroblast Membrane Receptors as Targets for PET-Imaging Tracers in Fibrosis & Fibrotic Cancer Stroma

Hind Lal
Associate Professor
University of Alabama at Birmingham

Ilya Korsunsky
Instructor of Medicine
Harvard Medical School

Day Two

Friday, November 11, 2022

2:00 pm | Cross-Tissue, Single-Cell Stromal Atlas Identifies Shared Pathological Fibroblasts Phenotypes in Four Chronic Inflammatory Diseases

Jeff Biernaskie
Professor
University of Calgary

Day 1 - Stream A - Afternoon

1:45 pm | Delving Into Transcriptional Programming & Immune Interactions That Influence Fibroblast Regenerative Competence

Jeremy O’Connell
Chief Scientific Officer & Co-Founder
Juvena Therapeutics

Day 1 - Stream A - Afternoon

2:30 pm | Turning Back the Clock Across Organs: Regenerating Fibrotic Loss & Preventing Progression Towards Organ Failure

Karim El Kasmi
Senior Principal Scientist
Boehringer Ingelheim

Ken Dower
Associate Research Fellow, Head of Fibrosis Discovery Biology
Pfizer

Day 1 - Stream A - Afternoon

1:15 pm |
Navigating Repairing & Regenerating Tissue to Address Fibrosis

Day 1 - Stream A - Morning

10:55 am |
Examining Novel In Vitro & In Vivo Modelling to Drive a New Era of Fibrotic Drug Development

Day Two

Friday, November 11, 2022

2:30 pm | Panel Discussion: What’s Missing? Uncovering the Questions that Need to Be Answered in the Next 12 Months of Research & Drug Development

Kevin Wei
Assistant Professor
Harvard University

Day 1 - Stream A - Morning

11:00 am | Understanding Fibroblast Heterogeneity in Target Organs Across Inflammatory & Fibrotic Diseases

Lee Borthwick
Chief Operating Officer
FibroFind

Day One

Thursday, November 10, 2022

4:30 pm | Dynamic Fibrogenesis in Human Precision Cut Tissue Slices: An Unrivalled Preclinical Platform for Development & Testing of Anti- Fibrotic Therapies

Lindsay McDonald
Assistant Professor
Ralph H. Johnson VA Medical Center

Day 1 - Stream A - Morning

12:15 pm | Harnessing Organ on a Chip Models to Improve Representation of the Human Condition

Michael Underhill
Professor
University of British Columbia

Day One

Thursday, November 10, 2022

8:00 am | Discussion Panel: Debating the Commonalities & Disparities Between the Different Fibrotic Disease Indications & Organ Specific Fibroses

Morten Karsdal
Chief Executive Officer
Nordic Bioscience

Day One

Thursday, November 10, 2022

9:00 am | Extracellular Matrix Remodeling is the Common Denominator in All Chronic Diseases

Nicolas Guisot
Research Fellow
RedX Pharma

Day Two

Friday, November 11, 2022

9:40 am | Pipeline Peak 4: GI Restricted ROCK Inhibitor RXC008 for The Treatment of Fibrotic Strictures in Crohn’s Disease

Philipp Tropberger
Senior Principal Scientist
Novartis

Day One

Thursday, November 10, 2022

8:00 am | Discussion Panel: Debating the Commonalities & Disparities Between the Different Fibrotic Disease Indications & Organ Specific Fibroses

Day Two

Friday, November 11, 2022

2:30 pm | Panel Discussion: What’s Missing? Uncovering the Questions that Need to Be Answered in the Next 12 Months of Research & Drug Development

Richard Stratton
Professor of Exeprimental Medicine
Centre for Rheumatology and Connective Tissue Diseases | UCL Divison of Medicine

Day 1 - Stream B - Morning

12:00 pm | Treating Scleroderma by Targeting Pro-Fibrotic Macrophages: Highlighting Biomarkers of M2-like Macrophages-Levels in Systemic Sclerosis

Rohan Manohar
Associate Director – Discovery Biology
Scholar Rock

Day Two

Friday, November 11, 2022

8:40 am | Pipeline Peak 1: Selective Targeting of Matrix-Associated TGFbeta1 Is An Attractive Approach for Anti-Fibrotic Therapy

Ryan Feaver
Executive Director & Head of Exploratory Biology
HemoShear

Day 1 - Stream A - Morning

11:45 am | Discovery of Novel Anti-Fibrotic Targets in an In Vitro Human Surrogate System of Nonalcoholic Steatohepatitis (NASH)

Shannon Turley
Vice President, Immunology & OMNI Biomarker Discovery
Genentech

Day 1 - Stream B - Afternoon

1:45 pm |
Panel Discussion:
Validating Biomarkers Across Trials & Diseases: Illuminating Learnings from the Lung, Kidney & Liver

1:15 pm |
Illuminating the Latest in Fibrotic Biomarkers Across Indications to Harness Predictive & Progressive Biomarkers In Clinical Development

Day 1 - Stream B - Morning

10:55 am |
Illuminating the Latest in Fibrotic Biomarkers Across Indications to Harness Predictive & Progressive Biomarkers In Clinical Development

Day One

Thursday, November 10, 2022

7:55 am |
Chair’s Opening Remarks

Thomas Fabre
Principal Scientist
Pfizer

Day Two

Friday, November 11, 2022

1:30 pm | Identifying a Broadly Fibrogenic Macrophage Subset Induced by Type 3 Inflammation in Human & Murine Liver & Lung Fibrosis

Will Richardson
Associate Professor of Bioengineering
University of Arizona